Skip to content
Screener

Halozyme Therapeutics HALO Other receivable — Accounts receivable, net and contract assets

Other product segments

Royalties
$297.23M+46.4%
Device partnered product sales
$104.32M+235%

Similar metrics at other companies

Churchill Downs logo
CHDNOther receivables — Accounts receivable
$24M-4.0%
Churchill Downs logo
CHDNTrade receivables — Accounts receivable
$58M+18.1%
Epsilon Energy logo
EPSNOther Receivables — Accounts Receivable Net Current
$0—
Hilton Grand Vacations logo
HGVOther receivables — Accounts Receivable
$0-100%
Pattern Group Inc. logo
PTRNOther receivables — Accounts receivable, gross
$25.22M—
Churchill Downs logo
CHDNSimulcast and online wagering receivables — Accounts receivable
$53M+6.0%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableGrossCurrent.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemJune 30,2026December 31,2025
Revenues under collaborative agreements6,01140,020
Royalty payments297,225259,298
Other product sales54,42765,117
Other receivable—1,612
Contract assets2,50015,000
Total accounts receivable and contract assets464,486450,879
Allowance for distribution fees and discounts(8,659)(9,606)
Total accounts receivable, net and contract assets$455,827$441,273

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's other receivable — accounts receivable, net and contract assets?
Halozyme Therapeutics (HALO) reported other receivable — accounts receivable, net and contract assets of $0 in Q2 2026.
What does other receivable — accounts receivable, net and contract assets mean?
This metric represents the aggregate value of outstanding receivables and contract assets specifically attributed to the 'Other' business segment. It captures amounts owed to the company by customers for products or services delivered, adjusted for potential uncollectible accounts, alongside recognized revenue for performance obligations satisfied but not yet billed. This figure is critical for assessing the liquidity and credit quality of the revenue streams generated within this specific operational segment.

Ask your AI about Halozyme Therapeutics's other receivable — accounts receivable, net and contract assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude